Company Overview and News
Gaming sector Maintain overweight. We continue to see multiple catalysts for the gaming sector. Gaming taxes could rise after the abolishment of the goods and services tax (GST) but the earnings impact would be moderate as the government is aware that sales could further flow out into the illegal market (for number forecasting operators [NFOs]) and regional competitors (for casinos).
GMALY G13 4715 GMALF GIGNF GEBHF GIGNY
KUALA LUMPUR: Kenanga Research said gaming companies, especially number forecast operators (NFO), have managed to outperform the overall markets over the past three months due to the tax holiday following the zero-rating of the goods and services tax.
GMALY 4715 GMALF GEBHF
KUALA LUMPUR: Trading volume on Bursa Malaysia, battered by the longest selling by foreign funds since the 14th General Election, saw it falling to 1.56 billion shares, the lowest since the start of 2018 as the US-China trade tensions rattled investor confidence. At 5pm, the FBM KLCI was a shade lower by 0.4 of a point to 0.02% to 1,665.68. Turnover was 1.56 billion shares valued at RM1.65bil. There were 365 gainers, 419 losers and 395 counters unchanged.
7293 PBLOF GMALF 4065 4197 5681 1295 6033 GMALY PNADF 4715 SMEBF BSMAF PNAGF GEBHF 1818
SINGAPORE (June 27): A number of stocks looking attractive on valuations are rising as the FTSE Bursa Malaysia KLCI Index’s price-to-earnings ratio has fallen below the historical average of 16 times amid continued selling by foreign investors, Credit Suisse analyst Danny Goh writes in note.
GMALY 4863 PBLOF 4715 GMALF MYTEF 1295
KUALA LUMPUR (June 14): The FBM KLCI narrowed its losses at market close today, but remained in the red in line with its regional peers, dragged by losses at Genting-related stocks and CIMB Group Holdings Bhd.
7251 MLYNF 5197 BATS 4162 GMALY 0133 1023 4715 PNAGF GEBHF HRGHY MLYBY SPMXF GMALF 5681 SNHHF 6432 5168 6033 CIMDF 5139 1155 PNADF SPMXY 0900 BSMAF 1818
(June 11): Southeast Asian stock markets trod water on Monday, ahead of a U.S.-North Korea summit that could lay the groundwork for ending a nuclear stand-off between the old foes, while investors also started to focus on key central bank meetings later this week.
GMALY 1155 MLYBY 4715 GMALF MLYNF
SINGAPORE, June 11 — South-east Asian stock markets trod water today ahead of a US-North Korea summit that could lay the groundwork for ending a nuclear stand-off between the old foes, while investors also started to focus on key central bank meetings later this week.
GMALY 1155 JGSMY SMIVY SVTMF MLYBY 4715 GMALF JGS MLYNF SM JGSHF
KUALA LUMPUR: Bursa Malaysia recorded the highest ever in trading value on Thursday at more than RM9bil as the FBM KLCI staged a steady rebound as the government unveiled more solid measures to strengthen the economy. At 5pm, the KLCI was up 21.34 points or 1.24% to 1,740.62. However, it managed to only recoup more than just one-third of the losses after falling more 56 points the previous day in a broad selloff.
PBLOF GMALF 4065 4197 5681 1295 6033 GMALY PNADF 4715 SMEBF 8869 5819 BSMAF PNAGF GEBHF 1818
KUALA LUMPUR: Foreign funds reacted to the unprecedented outcome of Malaysia’s General Election (GE14) by dumping RM2.48bil of local equities last week.
GMALY 5225 4715 GMALF 5681 Q0F IHHHF GEBHF
REVIEW: Bursa Malaysia in the post-election week reflected investor sentiment over the polling results with a show of confidence by local institutions keeping the market in good stead.
GMALY 3204 5226 PBLOF 4715 GMALF BATS 4162 1295 BSMAF 7078 1818
KUALA LUMPUR: Blue chips closed on a weak note on Wednesday ahead of the 14th General Election on May 9 as investors decided to stay on the sidelines. At 5pm, the FBM KLCI was down 18.34 points or 0.98% to 1,852.03. Turnover was 2.10 billion shares valued at RM2.43bil. There were 311 gainers, 551 losers and 381 counters unchanged. Hong Kong stocks fell as investors braced for trade talks between US and Chinese officials, and awaited the US Federal Reserve's upcoming policy statement, Reuters reported.
GMALY PNADF PBLOF 4715 GMALF 5819 1295 PNAGF GEBHF 6033
PETALING JAYA: Genting Bhd is optimistic that the Japan Integrated Resort Execution Bill will be tabled in this year’s Diet session, paving the way for the group to formally bid for its Japan gaming licence.
GMALY G13 4715 GMALF 2291 GIGNF GEBHF GIGNY
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET